Combining the assessment of HMGB1 concentrations in patient plasmas with other ICD-relevant parameters such as CALR expression and eIF2α phosphorylation in tumor biopsies should inform more accurately on the anticancer immune response (Figure 1). Here, HMGB1 is linked to neoplasm.